Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 22, 2010, Pages 10190-10195

  Kakoki, Masao ^a   Sullivan, Kelli A ^c   Backus, Carey ^c   Hayes, John M ^c   Oh, Sang Su ^c   Hua, Kunjie ^b   Gasim, Adil M H ^a   Tomita, Hirofumi ^a   Grant, Ruriko ^a   Nossov, Sarah B ^a   Kim, Hyung Suk ^a   Jennette, J Charles ^a   Feldman, Eva L ^b   Smithies, Oliver ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diabetes mellitus complications; Kinins

Indexed keywords

ALBUMIN; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; INSULIN; PROTEIN INSULIN 2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; GENE MUTATION; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HEAT SENSATION; HISTOPATHOLOGY; KALLIKREIN KININ SYSTEM; MALE; MITOCHONDRIAL DNA DEPLETION; MOUSE; NERVE CONDUCTION; NONHUMAN; OSTEOPATHIC MEDICINE; PRIORITY JOURNAL; URINARY EXCRETION;

ANIMALS; BONE DENSITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DNA, MITOCHONDRIAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; OSTEOPOROSIS; PHENOTYPE; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2;

MUS;

EID: 77953471168     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1005144107     Document Type: Article

References (56)

1. Skidgel RA, Erdös EG (1987) The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens A 9:243-259. (Pubitemid 17096549)
2. Campbell DJ, Kladis A, Duncan AM (1994) Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449. (Pubitemid 24102039)
3. Smithies O, Kim HS, Takahashi N, Edgell MH (2000) Importance of quantitative genetic variations in the etiology of hypertension. Kidney Int 58:2265-2280.
4. Rigat B, et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346. (Pubitemid 20370444)
5. Lachurié ML, Azizi M, Guyene TT, Alhenc-Gelas F, Ménard J (1995) Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91:2933-2942.
6. Marre M, et al. (1994) Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388. (Pubitemid 24064244)
7. Stephens JW, Dhamrait SS, Acharya J, Humphries SE, Hurel SJ (2006) A common variant in the ACE gene is associated with peripheral neuropathy in women with type 2 diabetes mellitus. J Diabetes Complications 20:317-321. (Pubitemid 44292531)
8. Rabensteiner D, et al. (1999) ACE gene polymorphism and proliferative retinopathy in type 1 diabetes: Results of a case-control study. Diabetes Care 22:1530-1535. (Pubitemid 29418251)
9. Cambien F, et al. (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644.
10. Doi Y, et al. (1997) Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis 132:145-150. (Pubitemid 27311005)
11. Sanada M, et al. (2004) Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis 176:387-392. (Pubitemid 39369530)
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462.
13. Malik RA, et al. (1998) Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised double-blind controlled trial. Lancet 352:1978-1981.
14. Zheng Z, Chen H, Xu X, Li C, Gu Q (2007) Effects of angiotensin- converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res 84:745-752. (Pubitemid 46400640)
15. Pérez-Castrillón JL, et al. (2003) Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: Relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 16:453-459.
16. Lynn H, Kwok T, Wong SY, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584-588.
17. Mancini GB, et al. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94:258-265.
18. Bodin S, et al. (2009) Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 76:395-403.
19. Kakoki M, Takahashi N, Jennette JC, Smithies O (2004) Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 101:13302-13305. (Pubitemid 39209660)
20. Kakoki M, et al. (2006) Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 116:1302-1309.
21. Lagneux C, Bader M, Pesquero JB, Demenge P, Ribuot C (2002) Detrimental implication of B1 receptors in myocardial ischemia: Evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2:815-822. (Pubitemid 34603126)
22. Xu J, et al. (2005) Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45:747-753. (Pubitemid 40418376)
23. Kakoki M, McGarrah RW, Kim HS, Smithies O (2007) Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 104:7576-7581. (Pubitemid 47185948)
24. Cayla C, et al. (2007) Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 21:1689-1698. (Pubitemid 46855614)
25. Tanhauser SM, Laipis PJ (1995) Multiple deletions are detectable in mitochondrial DNA of aging mice. J Biol Chem 270:24769-24775.
26. Riser BL, et al. (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25-38. (Pubitemid 30020423)
27. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA (1993) Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818. (Pubitemid 23069947)
28. Minchenko AG, et al. (2003) Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 17:1514-1516.
29. Sanderson N, et al. (1995) Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92:2572-2576.
30. Yokoi H, et al. (2008) Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 73:446-455. (Pubitemid 351186294)
31. Hocher B, et al. (1997) Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380-1389. (Pubitemid 27142776)
32. Tuominen JT, Impivaara O, Puukka P, Rönnemaa T (1999) Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196-1200. (Pubitemid 29293977)
33. Sullivan KA, et al. (2007) Mouse models of diabetic neuropathy. Neurobiol Dis 28:276-285.
34. Couture R, Girolami JP (2004) Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 500:467-485. (Pubitemid 39304028)
35. Spillmann F, et al. (2002) Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload- induced cardiomyopathy. Int Immunopharmacol 2:1823-1832. (Pubitemid 35373923)
36. Duka I, et al. (2001) Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res 88:275-281. (Pubitemid 32173750)
37. Drummond GR, Cocks TM (1995) Endothelium-dependent relaxations mediated by inducible B1 and constitutive B2 kinin receptors in the bovine isolated coronary artery. Br J Pharmacol 116:2473-2481.
38. Sangsree S, Brovkovych V, Minshall RD, Skidgel RA (2003) Kininase I-type carboxypeptidases enhance nitric oxide production in endothelial cells by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ Physiol 284:H1959-H1968. (Pubitemid 36622405)
39. Savard M, et al. (2008) Expression of endogenous nuclear bradykinin B2 receptors mediating signaling in immediate early gene activation. J Cell Physiol 216:234-244. (Pubitemid 351813114)
40. Schanstra JP, et al. (2003) Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 284:H1904-H1908.
41. Brown GC, Bolaños JP, Heales SJ, Clark JB (1995) Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration. Neurosci Lett 193:201-204.
42. Brunori M, et al. (2004) Control of cytochrome c oxidase activity by nitric oxide. Biochim Biophys Acta 1655:365-371. (Pubitemid 38526200)
43. Kakoki M, Smithies O (2009) The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 75:1019-1030.
44. Lee I, et al. (2005) cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity. J Biol Chem 280:6094-6100. (Pubitemid 40280094)
45. Piccoli C, et al. (2006) cAMP controls oxygen metabolism in mammalian cells. FEBS Lett 580:4539-4543. (Pubitemid 44118245)
46. Mikrut K, et al. (2001) The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia. Diabetes Res Clin Pract 51:79-85. (Pubitemid 32140860)
47. Gabra BH, Berthiaume N, Sirois P, Nantel F, Battistini B (2006) The kinin system mediates hyperalgesia through the inducible bradykinin B1 receptor subtype: Evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy. Biol Chem 387:127-143. (Pubitemid 43221825)
48. Vileikyte L, et al. (2005) Diabetic peripheral neuropathy and depressive symptoms: The association revisited. Diabetes Care 28:2378-2383. (Pubitemid 41384280)
49. Brechter AB, Lerner UH (2007) Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. Arthritis Rheum 56:910-923.
50. Alexiou T, et al. (2005) Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. J Hypertens 23:945-954. (Pubitemid 40637912)
51. Duka I, et al. (2001) Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 38:1355-1360. (Pubitemid 34033415)
52. Krege JH, Hodgin JB, Hagaman JR, Smithies O (1995) A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115.
53. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F (2001) Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med 31:331-335. (Pubitemid 32675338)
54. Wiggin TD, et al. (2009) Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58:1634-1640.
55. Saito T, Sumithran E, Glasgow EF, Atkins RC (1987) The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 32:691-699. (Pubitemid 17152399)
56. Pichler RH, et al. (1995) Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J Am Soc Nephrol 6:1186-1196.